Amylou Dueck, PhD
@biostatgirl.bsky.social
Oncology & Patient-Reported Outcomes Biostatistician looking for a new social media home. I love bar charts too. Opinions are my own.
https://duecklab.github.io
https://duecklab.github.io
Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs @christinayap.bsky.social
May 18, 2025 at 10:29 PM
Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs @christinayap.bsky.social
What an incredible week in Casablanca, Morocco, for @ash.hematology.org Clinical Research Training Institute & Training Day, Mediterranean, Middle East, and Northern Africa. I’m so inspired by the growth of the trainees this week & I’m excited to see the future #hematology leaders they become! #CRTI
April 5, 2025 at 12:25 PM
What an incredible week in Casablanca, Morocco, for @ash.hematology.org Clinical Research Training Institute & Training Day, Mediterranean, Middle East, and Northern Africa. I’m so inspired by the growth of the trainees this week & I’m excited to see the future #hematology leaders they become! #CRTI
Onsite retreat today - my fellow biostatisticians spelling out MAYO!
February 11, 2025 at 9:00 PM
Onsite retreat today - my fellow biostatisticians spelling out MAYO!
The fearless leaders of #SISAQOL: Anders Ingelgaard & Madeline Pe — thank you for your vision and work to enhance PRO statistical analysis for everyone!
February 4, 2025 at 2:50 PM
The fearless leaders of #SISAQOL: Anders Ingelgaard & Madeline Pe — thank you for your vision and work to enhance PRO statistical analysis for everyone!
Stakeholder panel at #SISAQOL. Interesting discussion about whether collection of PROs post-progression is feasible, how to make PROs less burdensome, & where to place PROs in the hierarchy of clinical trial endpoints. Universal agreement that SISAQOL moves the field forward!
February 4, 2025 at 2:36 PM
Stakeholder panel at #SISAQOL. Interesting discussion about whether collection of PROs post-progression is feasible, how to make PROs less burdensome, & where to place PROs in the hierarchy of clinical trial endpoints. Universal agreement that SISAQOL moves the field forward!
Coming soon from #SISAQOL: guidebook, interactive table, glossary, patient material, and more! Will be posted on the SISAQOL website. www.sisaqol-imi.org
February 4, 2025 at 2:34 PM
Coming soon from #SISAQOL: guidebook, interactive table, glossary, patient material, and more! Will be posted on the SISAQOL website. www.sisaqol-imi.org
Coming soon from #SISAQOL for patient advocates & patient research partners: checklist for reviewing PRO measures in protocols, and checklist for reviewing visualizations in cancer clinical trials.
February 4, 2025 at 11:19 AM
Coming soon from #SISAQOL for patient advocates & patient research partners: checklist for reviewing PRO measures in protocols, and checklist for reviewing visualizations in cancer clinical trials.
Harmonized terms to replace the vague term “MID” from #SISAQOL! Need to be clear about whether you are talking about within-patient change (eg, responder analysis) or three group-level options (mean comparisons within or between groups - see slides).
February 4, 2025 at 10:14 AM
Harmonized terms to replace the vague term “MID” from #SISAQOL! Need to be clear about whether you are talking about within-patient change (eg, responder analysis) or three group-level options (mean comparisons within or between groups - see slides).
This #SISAQOL #dataviz recommendation gets a dedicated post. While I agree in general with including sample size, missing data, & incurrent event information on all graphs for clarity, three lines of text per arm may be infeasible for multi-arm trials and may be more readable in a standalone table.
February 4, 2025 at 10:13 AM
Excited that #SISAQOL included recommendations about #dataviz for #patientreportedoutcomes! Graphs vary by audience consistent with prior literature. Include p-values for preplanned tests only, and use consistent y-axis scaling throughout your paper.
February 4, 2025 at 10:11 AM
Excited that #SISAQOL included recommendations about #dataviz for #patientreportedoutcomes! Graphs vary by audience consistent with prior literature. Include p-values for preplanned tests only, and use consistent y-axis scaling throughout your paper.
Next #SISAQOL turns to #patientreportedoutcomes in single-arm trials. PRO objectives should be clearly defined & can be descriptive (more common) or comparative to historical control data. Important to consider missing data & incurrent events as in randomized trials.
February 4, 2025 at 9:21 AM
Next #SISAQOL turns to #patientreportedoutcomes in single-arm trials. PRO objectives should be clearly defined & can be descriptive (more common) or comparative to historical control data. Important to consider missing data & incurrent events as in randomized trials.
Next #SISAQOL highlights involve missing data. Need to separate missing data from intercurrent events, and recommendations reinforce using “completion rate” & “available data rate” - quit using “compliance rate” in your papers! Finally, avoid biased missing data approaches.
February 4, 2025 at 9:19 AM
Next #SISAQOL highlights involve missing data. Need to separate missing data from intercurrent events, and recommendations reinforce using “completion rate” & “available data rate” - quit using “compliance rate” in your papers! Finally, avoid biased missing data approaches.
Diving into #SISAQOL recommendations. First highlights involve handling death or other intercurrent events. Basically there is no standard approach but need to be clear in the approach that you are using. Some new language here that many folks might not be familiar with…
February 4, 2025 at 9:18 AM
Diving into #SISAQOL recommendations. First highlights involve handling death or other intercurrent events. Basically there is no standard approach but need to be clear in the approach that you are using. Some new language here that many folks might not be familiar with…
Excited for a full day of new #SISAQOL recommendations for the statistical analysis of #patientreportedoutcomes in cancer clinical trials!
February 4, 2025 at 8:32 AM
Excited for a full day of new #SISAQOL recommendations for the statistical analysis of #patientreportedoutcomes in cancer clinical trials!
FDA panel on recent drug approvals in breast cancer at #SABCS24. Comparison of adjuvant CDK4/6 inhibitor trials, and lots of discussion about need for better dose optimization earlier in drug development.
December 10, 2024 at 7:17 PM
FDA panel on recent drug approvals in breast cancer at #SABCS24. Comparison of adjuvant CDK4/6 inhibitor trials, and lots of discussion about need for better dose optimization earlier in drug development.
First ever statistician meet up at #ASH24! Appreciate that @ash-hematology.bsky.social is working to foster broader statistician engagement in the annual meeting and the broader hematology field. @susanmgeyer.bsky.social
December 8, 2024 at 12:25 AM
First ever statistician meet up at #ASH24! Appreciate that @ash-hematology.bsky.social is working to foster broader statistician engagement in the annual meeting and the broader hematology field. @susanmgeyer.bsky.social
Free multiple myeloma response criteria from the pee! Excellent #ASH24 presentation by @rahulbanerjeemd.bsky.social showing that removing 24-hr urine changes response for only 1.1% of 645 patients in the BMT CTN 0702 clinical trial.
December 7, 2024 at 6:20 PM
Free multiple myeloma response criteria from the pee! Excellent #ASH24 presentation by @rahulbanerjeemd.bsky.social showing that removing 24-hr urine changes response for only 1.1% of 645 patients in the BMT CTN 0702 clinical trial.